Business
NRx Pharmaceuticals Initiates Senior Level Finance and Business Initiatives with Luxembourg Ministry of the Economy, BNP Paribas, and Vaccine Manufacturing Partners for BriLife® COVID-19 Vaccine Production
- NRx Enters into Negotiations for Financing and Manufacturing Capacity with BNP Paribas to serve European and Adjacent Markets - Tech Transfer and Scaleup of
About this update from Nrx Pharmaceuticals, Inc.
[{"type":"text","content":"- NRx Enters into Negotiations for Financing and Manufacturing Capacity with BNP Paribas to serve European and Adjacent Markets\n - Tech Transfer and Scaleup of BriLife™ COVID-19 Vaccine to Commence in November 2021\n - Targeting Initiation of GMP Vaccine Manufacture in First Half of 2022\n\n\nRADNOR, Pa., Nov. 5, 2021 /PRNewswire/ -- NRx Pharmaceuticals (NASDAQ: NRXP), via its subsidiary, NRx Luxembourg (NRx), has concluded a business mission to Luxembourg at the invitation of the Luxembourg Ministry of the Economy in preparation for the establishment of vaccine manufacturing capability to serve European and adjacent markets. NRx Luxembourg has been granted an operating company business license by the Luxembourg government and has established a commercial banking relationship with BNP Paribas (Luxembourg), managed by BNP's Head of Global Trade Solutions. NRx is currently negotiating a comprehensive banking and finance solution in preparation for tech transfer, scale-up, and manufacture of the BriLife™ vaccine.\n\n \n \n \n \n \n \n\n \nWe are fortunate that Luxembourg has shown us a confluence of unique technological capability, an enthusiastic financing environment, and a set of government priorities that include the type of environmentally friendly, high technology, health-tec manufacturing we require to advance BriLife to the next level. NRx has agreed to a tech transfer and scale-up contract with an advanced viral vector, contract research, and manufacturing organization in the Luxembourg region, with the objective to advance the BriLife vaccine from its current research scale platform to a scalable, adherent cell viral vector manufacturing platform that conforms to Good Manufacturing Practices (GMP) and other regulatory requirements.\nNRx and BNP's Head of Global Trade Solutions have met with Luxembourg's Directorate of Research and Innovation of the Ministry of the Economy to begin framing a vaccine manufacturing structure with government support that is intended to have the capability of delivering in excess of 300 million doses per year of vaccine at initial scale.\n\"As we begin to understand the potential of the BriLife vaccine to resist the Delta variant and other emerging variants of concern, we are working to put in place the manufacturing backbone that will enable us to begin building a large scale capability to d...